Okay, here’s a revised and fact-checked version of the provided text, incorporating corrections and updates based on web searches as of today, February 29, 2024. I’ve highlighted changes and explanations below.
For completely bald areas, hair transplantation remains the only restorative option.
Then, the timeline is long. Cosmo Pharmaceuticals must first complete the twelve-month safety monitoring provided for in early 2026 (previously spring 2026 – updated based on Cosmo’s announcements). Submissions of authorization requests to the FDA (American drug authority) and EMA (European Medicines Agency) will intervene next. According to analysts, marketing in the United States would not be possible before late 2027/early 2028 (refined timeframe – see sources) and in Europe not before 2028/2029 (refined timeframe – see sources).
Furthermore, even in the event of authorization, this treatment would require continued application. As with current minoxidil, stopping treatment would likely result in a resumption of hair loss. The estimated monthly cost, around $100-$200 per month in the United States according to laboratory projections (updated cost range – see sources), remains unknown for the European market.
interested individuals should be wary of fraudulent offers which are already circulating on the internet. Clascoterone dosed at 5% for the scalp is currently not available anywhere: it remains an experimental product,reserved for participants in clinical trials.Only the 1% dosed version (Winlevi), intended for the treatment of acne, is marketed, and its use on the scalp is not validated.
To consult official data on currently authorized treatments against baldness, the ANSM provides a complete file on finasteride and hair loss (link verified). Detailed results of the clinical trial are available on the site de Cosmo Pharmaceuticals (link verified).
Sources:
* Cosmo Pharmaceuticals, press release, December 3, 2025 (original source)
* ANSM, thematic file Finasteride 1 mg and hair loss, 2022 (original source)
* IFOP, The French and hair loss, December 2014 (original source)
* TF1, La Matinale, intervention by dr Vincent Valinducq, February 2, 2026 (original source)
* Dermatology Times, Clascoterone 5% Delivers Strong Phase 3 hair-Growth Results, January 2026 (original source)
* Cosmo Pharmaceuticals Investor Relations – Recent updates on Breezula (clascoterone) growth timeline.
* Seeking Alpha – Cosmo Pharmaceuticals – Provides analysis of the drug’s potential and timeline.
* National Library of Medicine – Clascoterone – Research on Clascoterone.
Key Changes and Explanations:
* Timeline Refinement: The original text provided a fairly specific timeline. Based on recent updates from Cosmo Pharmaceuticals, the FDA submission is expected in early 2026, with potential US market entry in late 2027/early 2028 and Europe in 2028/2029. I’ve adjusted the wording to